文献速递心力衰竭与心肌病冠心病

克隆性造血相关突变与慢性缺血性心力衰竭预后的关联

Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure.
PubMed 文献 · JAMA Cardiol · 2019-01-01

该研究对200例慢性缺血性心力衰竭患者进行骨髓单个核细胞深度靶向扩增子测序,检测克隆性造血不确定潜能(CHIP)突变,并分析其与长期预后的关系。中位随访4.4年,38例(18.5%)检出CHIP突变,其中TET2或DNMT3A突变者长期临床结局显著更差,且突变等位基因频率与结局呈剂量-反应关联。

要点

  • 慢性缺血性心衰患者中CHIP突变检出率为18.5%,常见基因为DNMT3A、TET2。
  • 携带TET2或DNMT3A突变者死亡或心衰住院风险独立升高(HR 2.1)。
  • 突变等位基因频率与不良结局呈显著剂量-反应关联。

核心结论

  • 造血细胞体细胞突变,尤其是TET2和DNMT3A突变,可能与慢性缺血性心力衰竭的进展和不良预后显著相关。

主要发现

  • 200例患者中38例(18.5%)检出至少0.02变异等位基因频率的体细胞突变,常见于DNMT3A(14例)、TET2(9例)、KDM6A(4例)和BCOR(3例)。
  • CHIP携带者年龄更大且高血压病史更常见。
  • 中位随访4.4年期间,53例死亡,23例因心衰住院。
  • 携带DNMT3A或TET2突变者长期临床结局显著差于非CHIP携带者。

临床怎么用

  • 对慢性缺血性心衰患者,检测CHIP相关突变(尤其TET2、DNMT3A)可能有助于风险分层。
  • 未来需在更大队列中验证,并探索针对特定炎症通路的精准治疗策略。

局限性

  • 研究样本量有限(200例),需在更大队列中验证发现。
  • 研究为单中心观察性分析,未报告因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Somatic mutations causing clonal expansion of hematopoietic cells (clonal hematopoiesis of indeterminate potential [CHIP]) are increased with age and associated with atherosclerosis and inflammation. Age and inflammation are the major risk factors for heart failure, yet the association of CHIP with heart failure in humans is unknown. OBJECTIVE: To assess the potential prognostic significance of CHIP in patients with chronic heart failure (CHF) owing to ischemic origin. DESIGN, SETTING, AND PARTICIPANTS: We analyzed bone marrow-derived mononuclear cells from 200 patients with CHF by deep targeted amplicon sequencing to detect the presence of CHIP and associated such with long-term prognosis in patients with CHF at University Hospital Frankfurt, Frankfurt, Germany. Data were analyzed between October 2017 and April 2018. RESULTS: Median age of the patients was 65 years. Forty-seven mutations with a variant allele fraction (VAF) of at least 0.02 were found in 38 of 200 patients with CHF (18.5%). The somatic mutations most commonly occurred in the genes DNMT3A (14 patients), TET2 (9 patients), KDM6A (4 patients), and BCOR (3 patients). Patients with CHIP were older and more frequently had a history of hypertension. During a median follow-up of 4.4 years, a total of 53 patients died, and 23 patients required hospitalization for heart failure. There was a significantly worse long-term clinical outcome for patients with either DNMT3A or TET2 mutations compared with non-CHIP carriers. By multivariable Cox proportional regression analysis, the presence of somatic mutations within TET2 or DNMT3A (HR, 2.1; 95% CI, 1.1-4.0; P = .02, for death combined with heart failure hospitalization) and age (HR, 1.04; 95% CI, 1.01-1.07 per year; P = .005) but not a history of hypertension remained independently associated with adverse outcome. Importantly, there was a significant dose-response association between VAF and clinical outcome. CONCLUSIONS AND RELEVANCE: Our data suggest that somatic mutations in hematopoietic cells, specifically in the most commonly mutated CHIP driver genes TET2 and DNMT3A, may be significantly associated with the progression and poor prognosis of CHF. Future studies will have to validate our findings in larger cohorts and address whether targeting specific inflammatory pathways may be valuable for precision medicine in patients with CHF carrying specific mutations encoding for CHIP.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Dorsheimer L, Assmus B, Rasper T, et al. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. JAMA Cardiol. 2019. PMID: 30566180. doi:10.1001/jamacardio.2018.3965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。